dc.contributor.author | Fernandez-Rodriguez, Amanda | |
dc.contributor.author | Berenguer, Juan | |
dc.contributor.author | Jimenez-Sousa, Maria Angeles | |
dc.contributor.author | Guzman-Fulgencio, Maria | |
dc.contributor.author | Micheloud, Dariela | |
dc.contributor.author | Miralles, Pilar | |
dc.contributor.author | López, Juan Carlos | |
dc.contributor.author | Bellón, José María | |
dc.contributor.author | Aldamiz-Echevarria, Teresa | |
dc.contributor.author | Garcia-Broncano, Pilar | |
dc.contributor.author | Carrero, Ana | |
dc.contributor.author | Alvarez, Emilio | |
dc.contributor.author | Resino, Salvador | |
dc.date.accessioned | 2024-02-04T18:51:14Z | |
dc.date.available | 2024-02-04T18:51:14Z | |
dc.date.issued | 2013-12-15 | |
dc.identifier.citation | J Acquir Immune Defic Syndr. 2013 Dec 15;64(5):434-42. | es_ES |
dc.identifier.uri | http://hdl.handle.net/20.500.12105/17447 | |
dc.description.abstract | Objective: To assess the ability of the cirrhosis risk score (CRS) to predict liver fibrosis progression in HIV/hepatitis C virus (HCV)-coinfected patients. Design: Retrospective follow-up study. Methods: Based on a minimum follow-up time of 10 years with HCV infection, 190 HIV/HCV-coinfected patients were classified according to their METAVIR score: (1) 25 nonprogressor patients who did not develop fibrosis (F0) and (2) 165 progressor patients who developed fibrosis (F ≥ 1). Seven polymorphisms of CRS signature and IL28B genotype were performed using the GoldenGate assay. The CRS signature was calculated by naive Bayes formula as previously described. Results: Nonprogressors had CRS values significantly lower than progressors (0.61 versus 0.67; P = 0.043). Among the progressors, we observed similar CRS values through all the fibrosis stages (F1/F2/F3/F4). The percentage of patients with CRS > 0.70 (high risk of developing fibrosis) was higher in progressors than in nonprogressors; but the percentages with values between 0.50 and 0.70 (intermediate risk) and <0.50 (low risk) were quite similar for each of the fibrosis stages (P = 0.047). The area under the receiver-operating characteristic curve of CRS for discriminating nonprogressor versus progressor was 0.625 (P = 0.043). When clinical variables were considered (age at HCV infection, intravenous drug use, gender, IL28B, and HCV genotype), the area under the receiver-operating characteristic curve of CRS improved up to 0.739 (P < 0.001). Conclusions: CRS itself seems not to be a good marker for identifying HIV/HCV-coinfected patients who are at high risk of developing liver fibrosis. However, CRS score coupled with clinical factors might help to distinguish between nonprogressors and progressors patients. | es_ES |
dc.description.sponsorship | Supported by Fondo de Investigacion de Sanidad en España (FIS) (Spanish Health Founds for Research) Grants PI08/0738, PI11/00245; PI08/0928, and PI11/01556; Red Española de Investigación en SIDA (RIS) (AIDS Research Network) Grants RD12/0017/0024 and RD12/0017/0004; and “Fundación para la Investigación y la Prevención del Sida en España” (FIPSE) Grant 361020/10. A. F. R., M. G. F., P. G. B., and M. A. J. S. are supported by “Instituto de Salud Carlos III” Grants UIPY-1377/08, CM09/00031, FI12/00036, and CM10/00105, respectively. | es_ES |
dc.language.iso | eng | es_ES |
dc.publisher | Lippincott Williams & Wilkins (LWW) | es_ES |
dc.type.hasVersion | AM | es_ES |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ | * |
dc.subject | AIDS | es_ES |
dc.subject | Chronic hepatitis C | es_ES |
dc.subject | Genetic polymorphisms | es_ES |
dc.subject | Liver fibrosis | es_ES |
dc.subject | Predictive genetic markers | es_ES |
dc.subject.mesh | Genetic Markers | es_ES |
dc.subject.mesh | Adolescent | es_ES |
dc.subject.mesh | Adult | es_ES |
dc.subject.mesh | Coinfection | es_ES |
dc.subject.mesh | Female | es_ES |
dc.subject.mesh | Follow-Up Studies | es_ES |
dc.subject.mesh | HIV Infections | es_ES |
dc.subject.mesh | Hepatitis C, Chronic | es_ES |
dc.subject.mesh | Humans | es_ES |
dc.subject.mesh | Liver Cirrhosis | es_ES |
dc.subject.mesh | Male | es_ES |
dc.subject.mesh | Middle Aged | es_ES |
dc.subject.mesh | Polymorphism, Single Nucleotide | es_ES |
dc.subject.mesh | Prognosis | es_ES |
dc.subject.mesh | Retrospective Studies | es_ES |
dc.subject.mesh | Young Adult | es_ES |
dc.title | Prediction of hepatic fibrosis in patients coinfected with HIV and hepatitis C virus based on genetic markers | es_ES |
dc.type | research article | es_ES |
dc.rights.license | Attribution-NonCommercial-NoDerivatives 4.0 Internacional | * |
dc.identifier.pubmedID | 23797694 | es_ES |
dc.format.volume | 64 | es_ES |
dc.format.number | 5 | es_ES |
dc.format.page | 434-442 | es_ES |
dc.identifier.doi | 10.1097/QAI.0b013e3182a06eb6 | es_ES |
dc.contributor.funder | Instituto de Salud Carlos III | es_ES |
dc.contributor.funder | RETICS-Sida (RIS-ISCIII) (España) | es_ES |
dc.contributor.funder | Fundación para la Investigación y la Prevención del Sida en España | es_ES |
dc.description.peerreviewed | Sí | es_ES |
dc.identifier.e-issn | 1944-7884 | es_ES |
dc.relation.publisherversion | https://doi.org/10.1097/QAI.0b013e3182a06eb6 | es_ES |
dc.identifier.journal | Journal of acquired immune deficiency syndromes (1999) | es_ES |
dc.repisalud.centro | ISCIII::Centro Nacional de Microbiología | es_ES |
dc.repisalud.institucion | ISCIII | es_ES |
dc.rights.accessRights | open access | es_ES |
dc.relation.projectFECYT | info:eu-repo/grantAgreement/MICINN//PI11%2F00245/ES/Erradicación del VHC en pacientes coinfectados por VIH%2FVHC: efectos sobre la inflamación, el daño endotelial, la activación inmune y la aterosclerosis preclínica/ | es_ES |
dc.relation.projectFECYT | info:eu-repo/grantAgreement/MICINN//PI11%2F01556/ES/Erradicación del VHC en pacientes coinfectados por VIH%2FVHC: efectos sobre la inflamación, el daño endotelial, la activación inmune y la aterosclerosis preclínica/ | es_ES |
dc.relation.projectFECYT | info:eu-repo/grantAgreement/MINECO//RD12%2F0017%2F0024/ES/SIDA/ | es_ES |
dc.relation.projectFECYT | info:eu-repo/grantAgreement/MINECO//RD12%2F0017%2F0004/ES/SIDA/ | es_ES |
dc.relation.projectFECYT | info:eu-repo/grantAgreement/MICINN//CM09%2F00031/ES/CM09%2F00031/ | es_ES |
dc.relation.projectFECYT | info:eu-repo/grantAgreement/MINECO//FI12%2F00036/ES/FI12%2F00036/ | es_ES |
dc.relation.projectFECYT | info:eu-repo/grantAgreement/MICINN//CM10%2F00105/ES/CM10%2F00105/ | es_ES |
dc.relation.projectFIS | info:eu-repo/grantAgreement/ES/PI08/0738 | es_ES |
dc.relation.projectFIS | info:eu-repo/grantAgreement/ES/PI08/0928 | es_ES |
dc.relation.projectFIS | info:eu-repo/grantAgreement/ES/UIPY-1377/08 | es_ES |